Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison

• Үндсэн зохиолчид: Jiajie Lu (Зохиогч), Quanquan Zhang (Зохиогч), Xiaoning Guo (Зохиогч), Wei Liu (Зохиогч), Chunyang Xu (Зохиогч), Xiaowei Hu (Зохиогч), Jianqiang Ni (Зохиогч), Haifeng Lu (Зохиогч), Hongru Zhao (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2021-05-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducte...